Acute Myeloid Leukemia With Inv3 P21 Q26 2 Or T 3 3 P21 Q26 2 C2826172
A high-risk chromosomal abnormality in acute myeloid leukemia where genetic material on chromosome 3 is rearranged. It is more common in adults and is associated with aggressive disease and poor response to standard therapy. Novel treatment approaches are being studied.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Chest pain
Fatigue
(hematologic)Bleeding gums
(oral)Night sweats
(general)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Allogeneic Stem Cell Transplant
Early transplantation from a suitable donor is strongly recommended for this very high-risk genetic subtype. The transplant procedure includes conditioning chemotherapy and immunosuppression followed by donor cell infusion.
Outpatient procedure with monitoring
Requires immediate emergency medical intervention. Do not delay treatment.
Intensive Induction Chemotherapy
Aggressive multi-agent chemotherapy to achieve initial disease control. Hospital-based treatment with continuous monitoring for tumor lysis syndrome, infections, and other complications is essential.
Additional treatment options
Clinical Trial Enrollment
Given the poor prognosis of inv(3)/t(3;3) AML, enrollment in clinical trials investigating novel therapeutic agents is strongly encouraged. Targeted therapies and immunotherapies are actively being studied in this population.
medicationEnhanced Supportive Care Protocol
Intensified supportive care measures including inpatient management during neutropenia, broad-spectrum antimicrobials, and proactive blood product support to bridge patients through intensive therapy.
medicationMolecular Monitoring Program
Serial molecular testing using sensitive techniques to track disease burden. This allows for early intervention when molecular relapse is detected before clinical symptoms develop.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia With Inv3 P21 Q26 2 Or T 3 3 P21 Q26 2 C2826172?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022.
Kuchenbauer F, Kern W, Haferlach C, et al. Comprehensive analysis of cytogenetic abnormalities in acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Leukemia. 2020.
Lundberg P, Becker M, Hoffmann R, et al. Clinical outcomes and prognostic factors in patients with acute myeloid leukemia harboring 3q26 abnormalities. J Clin Oncol. 2021.
Zhang Y, Wang Q, Chen L, Liu R. Prognostic significance of inv(3)/t(3;3) in acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2023.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia With Inv3 P21 Q26 2 Or T 3 3 P21 Q26 2 C2826172. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy